antifungal

News
FDA says no to F2G’s novel antifungal

FDA says no to F2G’s novel antifungal

F2G’s attempt to end a two-decade drought in novel therapies for invasive fungal infections has hit a hurdle after the FDA said it was unable to approve its olorofim candi

News
Candida_albicans_2

FDA advisors back Cidara antifungal rezafungin

An FDA advisory committee has recommended approval of Cidara Therapeutics' once-weekly antifungal therapy rezafungin, setting it up to become the first new option for severe infections caus

News
mycamine_pack_shot

Sandoz bulks up with Mycamine ahead of spin-off

With a separation from parent company Novartis now confirmed, Sandoz has moved to strengthen its revenue base with the acquisition of global rights to mainstay antifungal drug Mycamine from